首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1538518

血脂異常症治療藥物市場報告：2030 年趨勢、預測與競爭分析

Dyslipidaemia Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2024年07月01日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

血脂異常症治療藥物的趨勢與預測

預計到2030年，全球血脂異常症藥物市場將達到約440億美元，2024年至2030年的複合年成長率為9.4%。這個市場的主要驅動力是糖尿病和血脂異常症患者數量的增加、世界上老年人數量的增加以及膽固醇水平異常和脂質相關疾病發生率的增加。全球血脂異常症藥物市場前景廣闊，醫院藥局和零售藥局市場充滿機會。

血脂異常症治療的分段治療

本研究按藥物類型、應用和地區預測了血脂異常症藥物的全球市場。

血脂異常症藥物市場洞察

Lucintel 預測，他汀類藥物預計將在預測期內實現高速成長。

在這個市場中，醫院藥局在預測期內可能仍佔較大佔有率。

預計北美在預測期內將經歷最高的成長。

常問問題

Q1.市場規模為：

A1. 預計到 2030 年，全球血脂異常症藥物市值將達到 440 億美元。

Q2.市場成長預測是多少：

A2. 2024年至2030年，全球血脂異常症治療藥物市場預計將以9.4%的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3.該市場的主要驅動力是糖尿病和血脂異常症患者數量的增加、世界上老年人數量的增加以及膽固醇水平異常和脂質相關疾病的發生頻率的增加。

Q4.市場的主要細分市場是：

A4. 由於醫院藥局市場和零售藥局市場的機遇，血脂異常症藥物市場的前景看好。

Q5.市場的主要企業是：

A5.血脂異常症治療藥物的主要企業如下：

AstraZeneca
Bayer
Amgen
Merck
Shionogi
Novartis
Pfizer
Bristol-Myers Squibb Company
Mylan
Abbott Laboratories

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計他汀類藥物在預測期內將經歷高速成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 預計北美地區在預測期內將出現最高成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

宏觀經濟趨勢（2018-2023）與預測（2024-2030）
全球血脂異常症治療藥物市場趨勢（2018-2023）與預測（2024-2030）
按藥物類型分類的全球血脂異常症藥物市場
- 非他汀類藥物
- 他汀類藥物
按應用分類的全球血脂異常症治療市場
- 醫院藥房
- 零售藥房
- 其他

第4章 2018-2030年區域市場趨勢及預測分析

按地區分類的全球血脂異常症藥物市場
北美血脂異常症治療市場
歐洲血脂異常症藥物市場
亞太地區血脂異常症異常藥物市場
其他地區血脂異常症治療藥物市場

第5章競爭分析

產品系列分析
業務整合
波特五力分析

第6章成長機會與策略分析

成長機會分析
- 全球血脂異常症藥物市場按藥物類型分類的成長機會
- 按應用分類的血脂異常症治療市場的成長機會
- 全球血脂異常症藥物市場成長機會（按地區）
全球血脂異常症藥物市場新趨勢
戰略分析
- 新產品開發
- 擴大全球血脂異常症藥物市場的容量
- 全球血脂異常症藥物市場的合併、收購與合資
- 認證和許可

第7章主要企業概況

AstraZeneca
Bayer
Amgen
Merck
Shionogi
Novartis
Pfizer
Bristol-Myers Squibb Company
Mylan
Abbott Laboratories

簡介目錄

Dyslipidaemia Drug Trends and Forecast

The future of the global dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Dyslipidaemia Drug by Segment

The study includes a forecast for the global dyslipidaemia drug by drug type, application, and region.

Dyslipidaemia Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

Non-Statins Drugs
Statins Drugs

Dyslipidaemia Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

Hospital Pharmacy
Retail Pharmacy
Others

Dyslipidaemia Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Dyslipidaemia Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dyslipidaemia drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dyslipidaemia drug companies profiled in this report include-

AstraZeneca
Bayer
Amgen
Merck
Shionogi
Novartis
Pfizer
Bristol-Myers Squibb Company
Mylan
Abbott Laboratories

Dyslipidaemia Drug Market Insights

Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Within this market, hospital pharmacy will remain larger segment over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Dyslipidaemia Drug Market

Market Size Estimates: Dyslipidaemia drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Dyslipidaemia drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Dyslipidaemia drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the dyslipidaemia drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dyslipidaemia drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the dyslipidaemia drug market size?

Answer: The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030.

Q2. What is the growth forecast for dyslipidaemia drug market?

Answer: The global dyslipidaemia drug market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the dyslipidaemia drug market?

Answer: The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

Q4. What are the major segments for dyslipidaemia drug market?

Answer: The future of the dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets.

Q5. Who are the key dyslipidaemia drug market companies?

Answer: Some of the key dyslipidaemia drug companies are as follows:

AstraZeneca
Bayer
Amgen
Merck
Shionogi
Novartis
Pfizer
Bristol-Myers Squibb Company
Mylan
Abbott Laboratories

Q6. Which dyslipidaemia drug market segment will be the largest in future?

Answer: Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Q7. In dyslipidaemia drug market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the dyslipidaemia drug market by drug type (non-statins drugs and statins drugs), application (hospital pharmacy, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Dyslipidaemia Drug Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Dyslipidaemia Drug Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Dyslipidaemia Drug Market by Drug Type
- 3.3.1: Non-Statins Drugs
- 3.3.2: Statins Drugs
3.4: Global Dyslipidaemia Drug Market by Application
- 3.4.1: Hospital Pharmacy
- 3.4.2: Retail Pharmacy
- 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Dyslipidaemia Drug Market by Region
4.2: North American Dyslipidaemia Drug Market
- 4.2.1: North American Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
- 4.2.2: North American Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
4.3: European Dyslipidaemia Drug Market
- 4.3.1: European Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
- 4.3.2: European Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
4.4: APAC Dyslipidaemia Drug Market
- 4.4.1: APAC Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
- 4.4.2: APAC Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
4.5: ROW Dyslipidaemia Drug Market
- 4.5.1: ROW Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
- 4.5.2: ROW Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Dyslipidaemia Drug Market by Drug Type
- 6.1.2: Growth Opportunities for the Global Dyslipidaemia Drug Market by Application
- 6.1.3: Growth Opportunities for the Global Dyslipidaemia Drug Market by Region
6.2: Emerging Trends in the Global Dyslipidaemia Drug Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Dyslipidaemia Drug Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dyslipidaemia Drug Market
- 6.3.4: Certification and Licensing